Particularities and problems of psychopharmacology in childhood and adolescence

被引：0
|
作者：
Gerlach, Manfred [1 ,3 ]
Renner, Tobias [2 ,3 ]
Romanos, Marcel [1 ,3 ]
机构：
[1] Univ Klin Wurzburg, Zentrum Psych Gesundheit, Klin & Kinder & Jugendpsychiatrie Psychosomat & Ps, Margarete Hoppel Pl 1, D-97080 Wurzburg, Germany
[2] Univ Klinikum Tubingen, Klin Psychiat Psychosomat & Psychotherapie Kindes, Tubingen, Germany
[3] Arbeitsgruppe Kinder & jugendl Psychopharmakol Arb, Homburg, Germany
来源：
BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ | 2023年 / 66卷 / 07期
关键词：
Drug approval; Off-label use; Pharmacovigilance; Adverse drug reactions; Efficacy;
D O I：
10.1007/s00103-023-03718-z
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
The drug treatment of mental illness in childhood and adolescence poses a particular clinical and legal challenge. Reasons for this include the often necessary off-label use and existing knowledge gaps regarding the long-term effects of the neuro-/psychotropic drugs used. In this article, the prerequisites for therapy with neuro/psychotropic drugs, such as the need for age-appropriate inclusion of children and adolescents in the decision-making and education process, as well as the evaluation of medication, the consideration of biological age- and maturation-related factors, and the special measures for off-label use, are discussed. We further discuss general problems in the development and use of neuro-/psychotropic drugs, such as the difficulties in relation to proof of effectiveness, reimbursement and liability issues of off-label administration, and the problems of conducting clinical trials with children and adolescents.
引用
收藏
页码：761 / 766
页数：6
相关论文
共 50 条
12345